speb/financial-data huggingface dataset:
LAB.V cash_flow (annual, 2023-09-30) — Proceeds From Stock Option Exercised: 164000.00
LAB.V cash_flow (annual, 2023-09-30) — Purchase Of PPE: -10961202.00
LAB.V balance_sheet (annual, 2023-09-30) — Receivables: 482315.00
LAB.V income_statement (annual, 2023-09-30) — Reconciled Cost Of Revenue: 17920.00
LAB.V income_statement (annual, 2023-09-30) — Reconciled Depreciation: 17920.00
LAB.V balance_sheet (annual, 2023-09-30) — Retained Earnings: -17431883.00
LAB.V income_statement (annual, 2023-09-30) — Salaries And Wages: 336923.00
LAB.V income_statement (annual, 2023-09-30) — Selling General And Administration: 723976.00
LAB.V balance_sheet (annual, 2023-09-30) — Share Issued: 170009979.00
LAB.V income_statement (annual, 2023-09-30) — Special Income Charges: -16000.00
LAB.V cash_flow (annual, 2023-09-30) — Stock Based Compensation: 336923.00
LAB.V balance_sheet (annual, 2023-09-30) — Stockholders Equity: 48637417.00
LAB.V balance_sheet (annual, 2023-09-30) — Tangible Book Value: 48637417.00
LAB.V income_statement (annual, 2023-09-30) — Tax Effect Of Unusual Items: -2755.12
LAB.V income_statement (annual, 2023-09-30) — Tax Provision: -165757.00
LAB.V income_statement (annual, 2023-09-30) — Tax Rate For Calcs: 0.17
LAB.V balance_sheet (annual, 2023-09-30) — Total Assets: 50454543.00
LAB.V balance_sheet (annual, 2023-09-30) — Total Capitalization: 48637417.00
LAB.V balance_sheet (annual, 2023-09-30) — Total Equity Gross Minority Interest: 48637417.00
LAB.V income_statement (annual, 2023-09-30) — Total Expenses: 1293120.00
LAB.V balance_sheet (annual, 2023-09-30) — Total Liabilities Net Minority Interest: 1817126.00
LAB.V balance_sheet (annual, 2023-09-30) — Total Non Current Assets: 39812719.00
LAB.V balance_sheet (annual, 2023-09-30) — Total Non Current Liabilities Net Minority Interest: 817809.00
LAB.V income_statement (annual, 2023-09-30) — Total Unusual Items: -16000.00
LAB.V income_statement (annual, 2023-09-30) — Total Unusual Items Excluding Goodwill: -16000.00
LAB.V cash_flow (annual, 2023-09-30) — Unrealized Gain Loss On Investment Securities: 0.00
LAB.V balance_sheet (annual, 2023-09-30) — Working Capital: 9642507.00
LAB.V income_statement (annual, 2024-09-30) — +Operating Expense: 881005.00
LAB.V income_statement (annual, 2024-09-30) — +Total Revenue: 0.00
LAB.V balance_sheet (annual, 2024-09-30) — Accounts Receivable: 117603.00
LAB.V cash_flow (annual, 2024-09-30) — Amortization Cash Flow: 10830.00
LAB.V cash_flow (quarterly, 2024-09-30) — Amortization Cash Flow: 2708.00
LAB.V cash_flow (annual, 2024-09-30) — Amortization Of Intangibles: 10830.00
LAB.V cash_flow (quarterly, 2024-09-30) — Amortization Of Intangibles: 2708.00
LAB.V cash_flow (annual, 2024-09-30) — Asset Impairment Charge: 49623.00
LAB.V income_statement (annual, 2024-09-30) — Basic Average Shares: 170009979.00
LAB.V income_statement (annual, 2024-09-30) — Basic EPS: -0.10
LAB.V cash_flow (annual, 2024-09-30) — Beginning Cash Position: 10081678.00
LAB.V cash_flow (annual, 2024-09-30) — Capital Expenditure: -3926359.00
LAB.V cash_flow (quarterly, 2024-09-30) — Capital Expenditure: -366811.00
LAB.V balance_sheet (annual, 2024-09-30) — Capital Stock: 61472277.00
LAB.V balance_sheet (annual, 2024-09-30) — Cash And Cash Equivalents: 6057040.00
LAB.V balance_sheet (annual, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 24214932.00
LAB.V cash_flow (annual, 2024-09-30) — Cash Flow From Continuing Financing Activities: 0.00
LAB.V cash_flow (quarterly, 2024-09-30) — Cash Flow From Continuing Financing Activities: 0.00
LAB.V cash_flow (annual, 2024-09-30) — Cash Flow From Continuing Investing Activities: -3926359.00
LAB.V cash_flow (annual, 2024-09-30) — Cash Flow From Continuing Operating Activities: -98279.00
LAB.V cash_flow (annual, 2024-09-30) — Change In Payables And Accrued Expense: -40768.00
LAB.V cash_flow (annual, 2024-09-30) — Change In Prepaid Assets: 29589.00
LAB.V cash_flow (annual, 2024-09-30) — Change In Receivables: 364712.00
LAB.V cash_flow (annual, 2024-09-30) — Change In Working Capital: 353533.00
LAB.V cash_flow (annual, 2024-09-30) — Changes In Cash: -4024638.00
LAB.V balance_sheet (annual, 2024-09-30) — Common Stock: 61472277.00
LAB.V balance_sheet (annual, 2024-09-30) — Common Stock Equity: 31305592.00
LAB.V income_statement (annual, 2024-09-30) — Cost Of Revenue: 10830.00
LAB.V income_statement (quarterly, 2024-09-30) — Cost Of Revenue: 2708.00
LAB.V balance_sheet (annual, 2024-09-30) — Current Assets: 24380777.00
LAB.V balance_sheet (annual, 2024-09-30) — Current Liabilities: 140153.00
LAB.V cash_flow (annual, 2024-09-30) — Deferred Income Tax: -817809.00
LAB.V cash_flow (annual, 2024-09-30) — Deferred Tax: -817809.00
LAB.V cash_flow (annual, 2024-09-30) — Depreciation Amortization Depletion: 10830.00
LAB.V cash_flow (quarterly, 2024-09-30) — Depreciation Amortization Depletion: 2708.00
LAB.V cash_flow (annual, 2024-09-30) — Depreciation And Amortization: 10830.00
LAB.V cash_flow (quarterly, 2024-09-30) — Depreciation And Amortization: 2708.00
LAB.V income_statement (annual, 2024-09-30) — Diluted Average Shares: 170009979.00
LAB.V income_statement (annual, 2024-09-30) — Diluted EPS: -0.10
LAB.V income_statement (annual, 2024-09-30) — Diluted NI Availto Com Stockholders: -17440179.00
LAB.V income_statement (annual, 2024-09-30) — EBIT: -891835.00
LAB.V income_statement (annual, 2024-09-30) — EBITDA: -881005.00
LAB.V cash_flow (annual, 2024-09-30) — End Cash Position: 6057040.00
LAB.V cash_flow (annual, 2024-09-30) — Financing Cash Flow: 0.00
LAB.V cash_flow (quarterly, 2024-09-30) — Financing Cash Flow: 0.00
LAB.V cash_flow (annual, 2024-09-30) — Free Cash Flow: -4024638.00
LAB.V cash_flow (annual, 2024-09-30) — Gain Loss On Sale Of PPE: 15953159.00
LAB.V income_statement (annual, 2024-09-30) — Gain On Sale Of Ppe: -15953159.00
LAB.V income_statement (annual, 2024-09-30) — Gain On Sale Of Security: -1684210.00
LAB.V income_statement (annual, 2024-09-30) — General And Administrative Expense: 560829.00
LAB.V balance_sheet (annual, 2024-09-30) — Gross PPE: 7064968.00
LAB.V balance_sheet (quarterly, 2024-09-30) — Gross PPE: 7064968.00
LAB.V income_statement (annual, 2024-09-30) — Gross Profit: -10830.00
LAB.V income_statement (quarterly, 2024-09-30) — Gross Profit: -2708.00
LAB.V income_statement (annual, 2024-09-30) — Impairment Of Capital Assets: 49623.00
LAB.V balance_sheet (annual, 2024-09-30) — Invested Capital: 31305592.00
LAB.V cash_flow (annual, 2024-09-30) — Investing Cash Flow: -3926359.00
LAB.V income_statement (annual, 2024-09-30) — Net Income: -17440179.00
LAB.V income_statement (annual, 2024-09-30) — Net Income Common Stockholders: -17440179.00
LAB.V income_statement (annual, 2024-09-30) — Net Income Continuous Operations: -17440179.00
LAB.V income_statement (annual, 2024-09-30) — Net Income From Continuing And Discontinued Operation: -17440179.00
LAB.V income_statement (annual, 2024-09-30) — Net Income From Continuing Operation Net Minority Interest: -17440179.00
LAB.V cash_flow (annual, 2024-09-30) — Net Income From Continuing Operations: -17440179.00
LAB.V income_statement (annual, 2024-09-30) — Net Income Including Noncontrolling Interests: -17440179.00
LAB.V cash_flow (annual, 2024-09-30) — Net Investment Purchase And Sale: 0.00
LAB.V balance_sheet (annual, 2024-09-30) — Net PPE: 7064968.00
LAB.V cash_flow (annual, 2024-09-30) — Net PPE Purchase And Sale: -3926359.00
LAB.V balance_sheet (annual, 2024-09-30) — Net Tangible Assets: 31305592.00
LAB.V balance_sheet (annual, 2024-09-30) — Non Current Deferred Liabilities: 0.00
LAB.V balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Liabilities: 0.00
LAB.V balance_sheet (annual, 2024-09-30) — Non Current Deferred Taxes Liabilities: 0.00
LAB.V balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 0.00
LAB.V income_statement (annual, 2024-09-30) — Normalized EBITDA: 16805987.00
LAB.V income_statement (annual, 2024-09-30) — Normalized Income: -545420.03
LAB.V cash_flow (annual, 2024-09-30) — Operating Cash Flow: -98279.00
LAB.V cash_flow (annual, 2024-09-30) — Operating Gains Losses: 15953159.00
LAB.V income_statement (annual, 2024-09-30) — Operating Income: -891835.00
LAB.V income_statement (annual, 2024-09-30) — Operating Revenue: 0.00
LAB.V balance_sheet (annual, 2024-09-30) — Ordinary Shares Number: 170009979.00
LAB.V balance_sheet (annual, 2024-09-30) — Other Equity Interest: 4705377.00
LAB.V income_statement (annual, 2024-09-30) — Other Gand A: 452475.00
LAB.V income_statement (annual, 2024-09-30) — Other Income Expense: -17366153.00
LAB.V income_statement (annual, 2024-09-30) — Other Non Operating Income Expenses: 320839.00
LAB.V income_statement (annual, 2024-09-30) — Other Operating Expenses: 320176.00
LAB.V balance_sheet (annual, 2024-09-30) — Other Properties: 7064968.00
LAB.V balance_sheet (quarterly, 2024-09-30) — Other Properties: 7064968.00
LAB.V balance_sheet (annual, 2024-09-30) — Other Short Term Investments: 18157892.00
LAB.V balance_sheet (annual, 2024-09-30) — Payables And Accrued Expenses: 140153.00
LAB.V balance_sheet (annual, 2024-09-30) — Prepaid Assets: 48242.00
LAB.V income_statement (annual, 2024-09-30) — Pretax Income: -18257988.00
LAB.V cash_flow (annual, 2024-09-30) — Proceeds From Stock Option Exercised: 0.00
LAB.V cash_flow (quarterly, 2024-09-30) — Proceeds From Stock Option Exercised: 0.00
LAB.V cash_flow (annual, 2024-09-30) — Purchase Of PPE: -3926359.00
LAB.V balance_sheet (annual, 2024-09-30) — Receivables: 117603.00
LAB.V income_statement (annual, 2024-09-30) — Reconciled Cost Of Revenue: 10830.00
LAB.V income_statement (quarterly, 2024-09-30) — Reconciled Cost Of Revenue: 2708.00
LAB.V income_statement (annual, 2024-09-30) — Reconciled Depreciation: 10830.00
LAB.V income_statement (quarterly, 2024-09-30) — Reconciled Depreciation: 2708.00
LAB.V balance_sheet (annual, 2024-09-30) — Retained Earnings: -34872062.00
LAB.V income_statement (annual, 2024-09-30) — Salaries And Wages: 108354.00
LAB.V cash_flow (annual, 2024-09-30) — Sale Of Investment: 0.00
LAB.V income_statement (annual, 2024-09-30) — Selling General And Administration: 560829.00
LAB.V balance_sheet (annual, 2024-09-30) — Share Issued: 170009979.00
LAB.V income_statement (annual, 2024-09-30) — Special Income Charges: -16002782.00
LAB.V cash_flow (annual, 2024-09-30) — Stock Based Compensation: 108354.00
LAB.V balance_sheet (annual, 2024-09-30) — Stockholders Equity: 31305592.00
LAB.V balance_sheet (annual, 2024-09-30) — Tangible Book Value: 31305592.00
LAB.V income_statement (annual, 2024-09-30) — Tax Effect Of Unusual Items: -792233.03
LAB.V income_statement (annual, 2024-09-30) — Tax Provision: -817809.00
LAB.V income_statement (annual, 2024-09-30) — Tax Rate For Calcs: 0.04
LAB.V balance_sheet (annual, 2024-09-30) — Total Assets: 31445745.00
LAB.V balance_sheet (annual, 2024-09-30) — Total Capitalization: 31305592.00
LAB.V balance_sheet (annual, 2024-09-30) — Total Equity Gross Minority Interest: 31305592.00
LAB.V income_statement (annual, 2024-09-30) — Total Expenses: 891835.00
LAB.V balance_sheet (annual, 2024-09-30) — Total Liabilities Net Minority Interest: 140153.00
LAB.V balance_sheet (annual, 2024-09-30) — Total Non Current Assets: 7064968.00
LAB.V balance_sheet (annual, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 0.00
LAB.V income_statement (annual, 2024-09-30) — Total Unusual Items: -17686992.00
LAB.V income_statement (annual, 2024-09-30) — Total Unusual Items Excluding Goodwill: -17686992.00
LAB.V cash_flow (annual, 2024-09-30) — Unrealized Gain Loss On Investment Securities: 1684210.00
LAB.V balance_sheet (annual, 2024-09-30) — Working Capital: 24240624.00
LAB.V income_statement (quarterly, 2024-12-31) — +Operating Expense: 154296.00
LAB.V income_statement (quarterly, 2024-12-31) — +Total Revenue: 0.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Accounts Receivable: 54865.00
LAB.V cash_flow (quarterly, 2024-12-31) — Amortization Cash Flow: 0.00
LAB.V cash_flow (quarterly, 2024-12-31) — Amortization Of Intangibles: 0.00
LAB.V income_statement (quarterly, 2024-12-31) — Basic Average Shares: 170009979.00
LAB.V income_statement (quarterly, 2024-12-31) — Basic EPS: -0.03
LAB.V cash_flow (quarterly, 2024-12-31) — Beginning Cash Position: 6057040.00
LAB.V cash_flow (quarterly, 2024-12-31) — Capital Expenditure: -57611.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Capital Stock: 61472277.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Cash And Cash Equivalents: 7765746.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 19454823.00
LAB.V cash_flow (quarterly, 2024-12-31) — Cash Flow From Continuing Investing Activities: 1750314.00
LAB.V cash_flow (quarterly, 2024-12-31) — Cash Flow From Continuing Operating Activities: -41608.00
LAB.V cash_flow (quarterly, 2024-12-31) — Change In Payables And Accrued Expense: -14239.00
LAB.V cash_flow (quarterly, 2024-12-31) — Change In Prepaid Assets: -1111.00
LAB.V cash_flow (quarterly, 2024-12-31) — Change In Receivables: 62738.00
LAB.V cash_flow (quarterly, 2024-12-31) — Change In Working Capital: 47388.00
LAB.V cash_flow (quarterly, 2024-12-31) — Changes In Cash: 1708706.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Common Stock: 61472277.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Common Stock Equity: 26555706.00
LAB.V income_statement (quarterly, 2024-12-31) — Cost Of Revenue: 0.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Current Assets: 19559041.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Current Liabilities: 110245.00
LAB.V cash_flow (quarterly, 2024-12-31) — Depreciation Amortization Depletion: 0.00
LAB.V cash_flow (quarterly, 2024-12-31) — Depreciation And Amortization: 0.00
LAB.V income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 170009979.00
LAB.V income_statement (quarterly, 2024-12-31) — Diluted EPS: -0.03
LAB.V income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: -4762218.00
LAB.V income_statement (quarterly, 2024-12-31) — EBIT: -154296.00
LAB.V income_statement (quarterly, 2024-12-31) — EBITDA: -154296.00
LAB.V cash_flow (quarterly, 2024-12-31) — End Cash Position: 7765746.00
LAB.V cash_flow (quarterly, 2024-12-31) — Free Cash Flow: -99219.00
LAB.V cash_flow (quarterly, 2024-12-31) — Gain Loss On Investment Securities: 1019575.00
LAB.V income_statement (quarterly, 2024-12-31) — Gain On Sale Of Security: -4660890.00
LAB.V income_statement (quarterly, 2024-12-31) — General And Administrative Expense: 101456.00
LAB.V income_statement (quarterly, 2024-12-31) — Gross Profit: 0.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Invested Capital: 26555706.00
LAB.V cash_flow (quarterly, 2024-12-31) — Investing Cash Flow: 1750314.00
LAB.V income_statement (quarterly, 2024-12-31) — Net Income: -4762218.00
LAB.V income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: -4762218.00
LAB.V income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: -4762218.00
LAB.V income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -4762218.00
LAB.V income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -4762218.00
LAB.V cash_flow (quarterly, 2024-12-31) — Net Income From Continuing Operations: -4762218.00
LAB.V income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: -4762218.00
LAB.V cash_flow (quarterly, 2024-12-31) — Net Investment Purchase And Sale: 1807925.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Net PPE: 7106910.00
LAB.V cash_flow (quarterly, 2024-12-31) — Net PPE Purchase And Sale: -57611.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Net Tangible Assets: 26555706.00
LAB.V income_statement (quarterly, 2024-12-31) — Normalized EBITDA: 4506594.00
LAB.V income_statement (quarterly, 2024-12-31) — Normalized Income: -101328.00
LAB.V cash_flow (quarterly, 2024-12-31) — Operating Cash Flow: -41608.00
LAB.V cash_flow (quarterly, 2024-12-31) — Operating Gains Losses: 1019575.00
LAB.V income_statement (quarterly, 2024-12-31) — Operating Income: -154296.00
LAB.V income_statement (quarterly, 2024-12-31) — Operating Revenue: 0.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Ordinary Shares Number: 170009979.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Other Equity Interest: 4717709.00
LAB.V income_statement (quarterly, 2024-12-31) — Other Gand A: 89124.00
LAB.V income_statement (quarterly, 2024-12-31) — Other Income Expense: -4607922.00
LAB.V income_statement (quarterly, 2024-12-31) — Other Non Operating Income Expenses: 52968.00
LAB.V income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 52840.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Other Short Term Investments: 11689077.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Payables And Accrued Expenses: 110245.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Prepaid Assets: 49353.00
LAB.V income_statement (quarterly, 2024-12-31) — Pretax Income: -4762218.00
LAB.V cash_flow (quarterly, 2024-12-31) — Purchase Of Investment: 0.00
LAB.V cash_flow (quarterly, 2024-12-31) — Purchase Of PPE: -57611.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Receivables: 54865.00
LAB.V income_statement (quarterly, 2024-12-31) — Reconciled Cost Of Revenue: 0.00
LAB.V income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 0.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Retained Earnings: -39634280.00
LAB.V income_statement (quarterly, 2024-12-31) — Salaries And Wages: 12332.00
LAB.V cash_flow (quarterly, 2024-12-31) — Sale Of Investment: 1807925.00
LAB.V income_statement (quarterly, 2024-12-31) — Selling General And Administration: 101456.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Share Issued: 170009979.00
LAB.V cash_flow (quarterly, 2024-12-31) — Stock Based Compensation: 12332.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Stockholders Equity: 26555706.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Tangible Book Value: 26555706.00
LAB.V income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
LAB.V income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Total Assets: 26665951.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Total Capitalization: 26555706.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Total Equity Gross Minority Interest: 26555706.00
LAB.V income_statement (quarterly, 2024-12-31) — Total Expenses: 154296.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Total Liabilities Net Minority Interest: 110245.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Total Non Current Assets: 7106910.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
LAB.V income_statement (quarterly, 2024-12-31) — Total Unusual Items: -4660890.00
LAB.V income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: -4660890.00
LAB.V cash_flow (quarterly, 2024-12-31) — Unrealized Gain Loss On Investment Securities: 3641315.00
LAB.V balance_sheet (quarterly, 2024-12-31) — Working Capital: 19448796.00
LAB.V income_statement (quarterly, 2025-03-31) — +Operating Expense: 160481.00
LAB.V income_statement (quarterly, 2025-03-31) — +Total Revenue: 0.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 22802.00
LAB.V cash_flow (quarterly, 2025-03-31) — Amortization Cash Flow: 0.00
LAB.V cash_flow (quarterly, 2025-03-31) — Amortization Of Intangibles: 0.00
LAB.V income_statement (quarterly, 2025-03-31) — Basic Average Shares: 170009979.00
LAB.V income_statement (quarterly, 2025-03-31) — Basic EPS: -0.01
LAB.V cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 7765746.00
LAB.V cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -27946.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Capital Stock: 61472277.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 17458009.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 18094921.00
LAB.V cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: 9764709.00
LAB.V cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: -72446.00
LAB.V cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: -29349.00
LAB.V cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: -9801.00
LAB.V cash_flow (quarterly, 2025-03-31) — Change In Receivables: 32063.00
LAB.V cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -7087.00
LAB.V cash_flow (quarterly, 2025-03-31) — Changes In Cash: 9692263.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Common Stock: 61472277.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 24626035.00
LAB.V income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 0.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Current Assets: 18176877.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 90503.00
LAB.V cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 0.00
LAB.V cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 0.00
LAB.V income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 170009979.00
LAB.V income_statement (quarterly, 2025-03-31) — Diluted EPS: -0.01
LAB.V income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -1966696.00
LAB.V income_statement (quarterly, 2025-03-31) — EBIT: -160481.00
LAB.V income_statement (quarterly, 2025-03-31) — EBITDA: -160481.00
LAB.V cash_flow (quarterly, 2025-03-31) — End Cash Position: 17458009.00
LAB.V cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -100392.00
LAB.V cash_flow (quarterly, 2025-03-31) — Gain Loss On Investment Securities: 5833995.00
LAB.V income_statement (quarterly, 2025-03-31) — Gain On Sale Of Security: -1259510.00
LAB.V income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 122522.00
LAB.V income_statement (quarterly, 2025-03-31) — Gross Profit: 0.00
LAB.V income_statement (quarterly, 2025-03-31) — Impairment Of Capital Assets: 604802.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Invested Capital: 24626035.00
LAB.V cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: 9764709.00
LAB.V income_statement (quarterly, 2025-03-31) — Minority Interests: 0.00
LAB.V income_statement (quarterly, 2025-03-31) — Net Income: -1966696.00
LAB.V income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -1966696.00
LAB.V income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -1966696.00
LAB.V income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -1966696.00
LAB.V income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -1966696.00
LAB.V cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -1966696.00
LAB.V income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -1966696.00
LAB.V cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: 9792655.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Net PPE: 6539661.00
LAB.V cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -27946.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 24626035.00
LAB.V income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 1703831.00
LAB.V income_statement (quarterly, 2025-03-31) — Normalized Income: -102384.00
LAB.V cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -72446.00
LAB.V cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: 5833995.00
LAB.V income_statement (quarterly, 2025-03-31) — Operating Income: -160481.00
LAB.V income_statement (quarterly, 2025-03-31) — Operating Revenue: 0.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 170009979.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 4754734.00
LAB.V income_statement (quarterly, 2025-03-31) — Other Gand A: 85497.00
LAB.V income_statement (quarterly, 2025-03-31) — Other Income Expense: -1806215.00
LAB.V income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 58097.00
LAB.V income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 37959.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 636912.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 90503.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 59154.00
LAB.V income_statement (quarterly, 2025-03-31) — Pretax Income: -1966696.00
LAB.V cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: 0.00
LAB.V cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -27946.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Receivables: 22802.00
LAB.V income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 0.00
LAB.V income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 0.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -41600976.00
LAB.V income_statement (quarterly, 2025-03-31) — Salaries And Wages: 37025.00
LAB.V cash_flow (quarterly, 2025-03-31) — Sale Of Investment: 9792655.00
LAB.V income_statement (quarterly, 2025-03-31) — Selling General And Administration: 122522.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Share Issued: 170009979.00
LAB.V income_statement (quarterly, 2025-03-31) — Special Income Charges: -604802.00
LAB.V cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 37025.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 24626035.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 24626035.00
LAB.V income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
LAB.V income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Total Assets: 24716538.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 24626035.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 24626035.00
LAB.V income_statement (quarterly, 2025-03-31) — Total Expenses: 160481.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 90503.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 6539661.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 0.00
LAB.V income_statement (quarterly, 2025-03-31) — Total Unusual Items: -1864312.00
LAB.V income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: -1864312.00
LAB.V cash_flow (quarterly, 2025-03-31) — Unrealized Gain Loss On Investment Securities: -4574485.00
LAB.V balance_sheet (quarterly, 2025-03-31) — Working Capital: 18086374.00
LAB.V income_statement (quarterly, 2025-06-30) — +Operating Expense: 177026.00
LAB.V income_statement (quarterly, 2025-06-30) — +Total Revenue: 0.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 81231.00
LAB.V cash_flow (quarterly, 2025-06-30) — Amortization Cash Flow: 0.00
LAB.V cash_flow (quarterly, 2025-06-30) — Amortization Of Intangibles: 0.00
LAB.V cash_flow (quarterly, 2025-06-30) — Asset Impairment Charge: 0.00
LAB.V income_statement (quarterly, 2025-06-30) — Basic Average Shares: 170009979.00
LAB.V income_statement (quarterly, 2025-06-30) — Basic EPS: 0.00
LAB.V cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 17458009.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Capital Stock: 61472277.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 17998360.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 17998360.00
LAB.V cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: 596596.00
LAB.V cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: -56245.00
LAB.V cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: 45398.00
LAB.V cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: 2547.00
LAB.V cash_flow (quarterly, 2025-06-30) — Change In Receivables: -58429.00
LAB.V cash_flow (quarterly, 2025-06-30) — Change In Working Capital: -10484.00
LAB.V cash_flow (quarterly, 2025-06-30) — Changes In Cash: 540351.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Common Stock: 61472277.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 24531565.00
LAB.V income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 0.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Current Assets: 18136198.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 242546.00
LAB.V cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 0.00
LAB.V cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 0.00
LAB.V income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 170009979.00
LAB.V income_statement (quarterly, 2025-06-30) — Diluted EPS: 0.00
LAB.V income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -126249.00
LAB.V income_statement (quarterly, 2025-06-30) — EBIT: -177026.00
LAB.V income_statement (quarterly, 2025-06-30) — EBITDA: -177026.00
LAB.V cash_flow (quarterly, 2025-06-30) — End Cash Position: 17998360.00
LAB.V cash_flow (quarterly, 2025-06-30) — Free Cash Flow: -47852.00
LAB.V income_statement (quarterly, 2025-06-30) — Gain On Sale Of Security: -48709.00
LAB.V income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 147459.00
LAB.V income_statement (quarterly, 2025-06-30) — Gross Profit: 0.00
LAB.V income_statement (quarterly, 2025-06-30) — Impairment Of Capital Assets: 0.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Invested Capital: 24531565.00
LAB.V cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: 596596.00
LAB.V income_statement (quarterly, 2025-06-30) — Net Income: -126249.00
LAB.V income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -126249.00
LAB.V income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -126249.00
LAB.V income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -126249.00
LAB.V income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -126249.00
LAB.V cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: -126249.00
LAB.V income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -126249.00
LAB.V cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: 588203.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Net PPE: 6637913.00
LAB.V cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: 8393.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 24531565.00
LAB.V income_statement (quarterly, 2025-06-30) — Normalized EBITDA: -128317.00
LAB.V income_statement (quarterly, 2025-06-30) — Normalized Income: -77540.00
LAB.V cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: -56245.00
LAB.V income_statement (quarterly, 2025-06-30) — Operating Income: -177026.00
LAB.V income_statement (quarterly, 2025-06-30) — Operating Revenue: 0.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 170009979.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Other Equity Interest: 4786513.00
LAB.V income_statement (quarterly, 2025-06-30) — Other Gand A: 115680.00
LAB.V income_statement (quarterly, 2025-06-30) — Other Income Expense: 50777.00
LAB.V income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 99486.00
LAB.V income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 29567.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Other Short Term Investments: 0.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 242546.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Prepaid Assets: 56607.00
LAB.V income_statement (quarterly, 2025-06-30) — Pretax Income: -126249.00
LAB.V cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: 8393.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Receivables: 81231.00
LAB.V income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 0.00
LAB.V income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 0.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -41727225.00
LAB.V income_statement (quarterly, 2025-06-30) — Salaries And Wages: 31779.00
LAB.V cash_flow (quarterly, 2025-06-30) — Sale Of Investment: 588203.00
LAB.V income_statement (quarterly, 2025-06-30) — Selling General And Administration: 147459.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Share Issued: 170009979.00
LAB.V income_statement (quarterly, 2025-06-30) — Special Income Charges: 0.00
LAB.V cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 31779.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 24531565.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 24531565.00
LAB.V income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
LAB.V income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Total Assets: 24774111.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 24531565.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 24531565.00
LAB.V income_statement (quarterly, 2025-06-30) — Total Expenses: 177026.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 242546.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 6637913.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 0.00
LAB.V income_statement (quarterly, 2025-06-30) — Total Unusual Items: -48709.00
LAB.V income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: -48709.00
LAB.V cash_flow (quarterly, 2025-06-30) — Unrealized Gain Loss On Investment Securities: 6902279.00
LAB.V balance_sheet (quarterly, 2025-06-30) — Working Capital: 17893652.00
LAB.V income_statement (annual, 2025-09-30) — +Operating Expense: 1305455.00
LAB.V income_statement (quarterly, 2025-09-30) — +Operating Expense: 813652.00
LAB.V income_statement (annual, 2025-09-30) — +Total Revenue: 0.00
LAB.V income_statement (quarterly, 2025-09-30) — +Total Revenue: 0.00
LAB.V balance_sheet (annual, 2025-09-30) — Accounts Receivable: 162567.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 162567.00
LAB.V cash_flow (annual, 2025-09-30) — Amortization Cash Flow: 0.00
LAB.V cash_flow (quarterly, 2025-09-30) — Amortization Cash Flow: 0.00
LAB.V cash_flow (annual, 2025-09-30) — Amortization Of Intangibles: 0.00
LAB.V cash_flow (quarterly, 2025-09-30) — Amortization Of Intangibles: 0.00
LAB.V cash_flow (annual, 2025-09-30) — Asset Impairment Charge: 648924.00
LAB.V cash_flow (quarterly, 2025-09-30) — Asset Impairment Charge: 44122.00
LAB.V income_statement (annual, 2025-09-30) — Basic Average Shares: 170009979.00
LAB.V income_statement (annual, 2025-09-30) — Basic EPS: -0.04
LAB.V cash_flow (annual, 2025-09-30) — Beginning Cash Position: 6057040.00
LAB.V cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 17998360.00
LAB.V cash_flow (annual, 2025-09-30) — Capital Expenditure: -651883.00
LAB.V cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -574719.00
LAB.V balance_sheet (annual, 2025-09-30) — Capital Stock: 61472277.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Capital Stock: 61472277.00
LAB.V balance_sheet (annual, 2025-09-30) — Cash And Cash Equivalents: 16766742.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 16766742.00
LAB.V balance_sheet (annual, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 16766742.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 16766742.00
LAB.V cash_flow (annual, 2025-09-30) — Cash Flow From Continuing Investing Activities: 11536900.00
LAB.V cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -574719.00
LAB.V cash_flow (annual, 2025-09-30) — Cash Flow From Continuing Operating Activities: -827198.00
LAB.V cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: -656899.00
LAB.V cash_flow (annual, 2025-09-30) — Change In Payables And Accrued Expense: 56515.00
LAB.V cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 54705.00
LAB.V cash_flow (annual, 2025-09-30) — Change In Prepaid Assets: 7316.00
LAB.V cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: 15681.00
LAB.V cash_flow (annual, 2025-09-30) — Change In Receivables: -44964.00
LAB.V cash_flow (quarterly, 2025-09-30) — Change In Receivables: -81336.00
LAB.V cash_flow (annual, 2025-09-30) — Change In Working Capital: 18867.00
LAB.V cash_flow (quarterly, 2025-09-30) — Change In Working Capital: -10950.00
LAB.V cash_flow (annual, 2025-09-30) — Changes In Cash: 10709702.00
LAB.V cash_flow (quarterly, 2025-09-30) — Changes In Cash: -1231618.00
LAB.V balance_sheet (annual, 2025-09-30) — Common Stock: 61472277.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Common Stock: 61472277.00
LAB.V balance_sheet (annual, 2025-09-30) — Common Stock Equity: 23841494.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 23841494.00
LAB.V income_statement (annual, 2025-09-30) — Cost Of Revenue: 0.00
LAB.V income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 0.00
LAB.V balance_sheet (annual, 2025-09-30) — Current Assets: 16970235.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Current Assets: 16970235.00
LAB.V balance_sheet (annual, 2025-09-30) — Current Liabilities: 281284.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 281284.00
LAB.V cash_flow (annual, 2025-09-30) — Deferred Income Tax: 0.00
LAB.V cash_flow (annual, 2025-09-30) — Deferred Tax: 0.00
LAB.V cash_flow (annual, 2025-09-30) — Depreciation Amortization Depletion: 0.00
LAB.V cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 0.00
LAB.V cash_flow (annual, 2025-09-30) — Depreciation And Amortization: 0.00
LAB.V cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 0.00
LAB.V income_statement (annual, 2025-09-30) — Diluted Average Shares: 170009979.00
LAB.V income_statement (annual, 2025-09-30) — Diluted EPS: -0.04
LAB.V income_statement (annual, 2025-09-30) — Diluted NI Availto Com Stockholders: -7609098.00
LAB.V income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -753935.00
LAB.V income_statement (annual, 2025-09-30) — EBIT: -1305455.00
LAB.V income_statement (quarterly, 2025-09-30) — EBIT: -813652.00
LAB.V income_statement (annual, 2025-09-30) — EBITDA: -1305455.00
LAB.V income_statement (quarterly, 2025-09-30) — EBITDA: -813652.00
LAB.V cash_flow (annual, 2025-09-30) — End Cash Position: 16766742.00
LAB.V cash_flow (quarterly, 2025-09-30) — End Cash Position: 16766742.00
LAB.V cash_flow (annual, 2025-09-30) — Free Cash Flow: -1479081.00
LAB.V cash_flow (quarterly, 2025-09-30) — Free Cash Flow: -1231618.00
LAB.V cash_flow (annual, 2025-09-30) — Gain Loss On Investment Securities: 7653319.00
LAB.V cash_flow (annual, 2025-09-30) — Gain Loss On Sale Of PPE: 0.00
LAB.V income_statement (annual, 2025-09-30) — Gain On Sale Of Ppe: 0.00
LAB.V income_statement (annual, 2025-09-30) — Gain On Sale Of Security: -5969109.00
LAB.V income_statement (quarterly, 2025-09-30) — Gain On Sale Of Security: 0.00
LAB.V income_statement (annual, 2025-09-30) — General And Administrative Expense: 1110525.00
LAB.V income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 739088.00
LAB.V income_statement (annual, 2025-09-30) — Gross Profit: 0.00
LAB.V income_statement (quarterly, 2025-09-30) — Gross Profit: 0.00
LAB.V income_statement (annual, 2025-09-30) — Impairment Of Capital Assets: 648924.00
LAB.V income_statement (quarterly, 2025-09-30) — Impairment Of Capital Assets: 44122.00
LAB.V balance_sheet (annual, 2025-09-30) — Invested Capital: 23841494.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Invested Capital: 23841494.00
LAB.V cash_flow (annual, 2025-09-30) — Investing Cash Flow: 11536900.00
LAB.V cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -574719.00
LAB.V income_statement (annual, 2025-09-30) — Net Income: -7609098.00
LAB.V income_statement (quarterly, 2025-09-30) — Net Income: -753935.00
LAB.V income_statement (annual, 2025-09-30) — Net Income Common Stockholders: -7609098.00
LAB.V income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -753935.00
LAB.V income_statement (annual, 2025-09-30) — Net Income Continuous Operations: -7609098.00
LAB.V income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -753935.00
LAB.V income_statement (annual, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -7609098.00
LAB.V income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -753935.00
LAB.V income_statement (annual, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -7609098.00
LAB.V income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -753935.00
LAB.V cash_flow (annual, 2025-09-30) — Net Income From Continuing Operations: -7609098.00
LAB.V cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -753935.00
LAB.V income_statement (annual, 2025-09-30) — Net Income Including Noncontrolling Interests: -7609098.00
LAB.V income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -753935.00
LAB.V cash_flow (annual, 2025-09-30) — Net Investment Purchase And Sale: 12188783.00
LAB.V cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: 0.00
LAB.V balance_sheet (annual, 2025-09-30) — Net PPE: 7152543.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Net PPE: 7152543.00
LAB.V cash_flow (annual, 2025-09-30) — Net PPE Purchase And Sale: -651883.00
LAB.V cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -574719.00
LAB.V balance_sheet (annual, 2025-09-30) — Net Tangible Assets: 23841494.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 23841494.00
LAB.V income_statement (annual, 2025-09-30) — Normalized EBITDA: 5312578.00
LAB.V income_statement (quarterly, 2025-09-30) — Normalized EBITDA: -769530.00
LAB.V income_statement (annual, 2025-09-30) — Normalized Income: -991065.00
LAB.V income_statement (quarterly, 2025-09-30) — Normalized Income: -709813.00
LAB.V cash_flow (annual, 2025-09-30) — Operating Cash Flow: -827198.00
LAB.V cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: -656899.00
LAB.V cash_flow (annual, 2025-09-30) — Operating Gains Losses: 7653319.00
LAB.V income_statement (annual, 2025-09-30) — Operating Income: -1305455.00
LAB.V income_statement (quarterly, 2025-09-30) — Operating Income: -813652.00
LAB.V income_statement (annual, 2025-09-30) — Operating Revenue: 0.00
LAB.V income_statement (quarterly, 2025-09-30) — Operating Revenue: 0.00
LAB.V balance_sheet (annual, 2025-09-30) — Ordinary Shares Number: 170009979.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 170009979.00
LAB.V balance_sheet (annual, 2025-09-30) — Other Equity Interest: 4850377.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 4850377.00
LAB.V income_statement (annual, 2025-09-30) — Other Gand A: 965525.00
LAB.V income_statement (quarterly, 2025-09-30) — Other Gand A: 675224.00
LAB.V income_statement (annual, 2025-09-30) — Other Income Expense: -6303643.00
LAB.V income_statement (quarterly, 2025-09-30) — Other Income Expense: 59717.00
LAB.V income_statement (annual, 2025-09-30) — Other Non Operating Income Expenses: 314390.00
LAB.V income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 103839.00
LAB.V income_statement (annual, 2025-09-30) — Other Operating Expenses: 194930.00
LAB.V income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 74564.00
LAB.V balance_sheet (annual, 2025-09-30) — Other Short Term Investments: 0.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 0.00
LAB.V balance_sheet (annual, 2025-09-30) — Payables And Accrued Expenses: 281284.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 281284.00
LAB.V balance_sheet (annual, 2025-09-30) — Prepaid Assets: 40926.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Prepaid Assets: 40926.00
LAB.V income_statement (annual, 2025-09-30) — Pretax Income: -7609098.00
LAB.V income_statement (quarterly, 2025-09-30) — Pretax Income: -753935.00
LAB.V cash_flow (annual, 2025-09-30) — Purchase Of PPE: -651883.00
LAB.V cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -574719.00
LAB.V balance_sheet (annual, 2025-09-30) — Receivables: 162567.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Receivables: 162567.00
LAB.V income_statement (annual, 2025-09-30) — Reconciled Cost Of Revenue: 0.00
LAB.V income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 0.00
LAB.V income_statement (annual, 2025-09-30) — Reconciled Depreciation: 0.00
LAB.V income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 0.00
LAB.V balance_sheet (annual, 2025-09-30) — Retained Earnings: -42481160.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -42481160.00
LAB.V income_statement (annual, 2025-09-30) — Salaries And Wages: 145000.00
LAB.V income_statement (quarterly, 2025-09-30) — Salaries And Wages: 63864.00
LAB.V cash_flow (annual, 2025-09-30) — Sale Of Investment: 12188783.00
LAB.V cash_flow (quarterly, 2025-09-30) — Sale Of Investment: 0.00
LAB.V income_statement (annual, 2025-09-30) — Selling General And Administration: 1110525.00
LAB.V income_statement (quarterly, 2025-09-30) — Selling General And Administration: 739088.00
LAB.V balance_sheet (annual, 2025-09-30) — Share Issued: 170009979.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Share Issued: 170009979.00
LAB.V income_statement (annual, 2025-09-30) — Special Income Charges: -648924.00
LAB.V income_statement (quarterly, 2025-09-30) — Special Income Charges: -44122.00
LAB.V cash_flow (annual, 2025-09-30) — Stock Based Compensation: 145000.00
LAB.V cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 63864.00
LAB.V balance_sheet (annual, 2025-09-30) — Stockholders Equity: 23841494.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 23841494.00
LAB.V balance_sheet (annual, 2025-09-30) — Tangible Book Value: 23841494.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 23841494.00
LAB.V income_statement (annual, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
LAB.V income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
LAB.V income_statement (annual, 2025-09-30) — Tax Provision: 0.00
LAB.V income_statement (annual, 2025-09-30) — Tax Rate For Calcs: 0.00
LAB.V income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.00
LAB.V balance_sheet (annual, 2025-09-30) — Total Assets: 24122778.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Total Assets: 24122778.00
LAB.V balance_sheet (annual, 2025-09-30) — Total Capitalization: 23841494.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 23841494.00
LAB.V balance_sheet (annual, 2025-09-30) — Total Equity Gross Minority Interest: 23841494.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 23841494.00
LAB.V income_statement (annual, 2025-09-30) — Total Expenses: 1305455.00
LAB.V income_statement (quarterly, 2025-09-30) — Total Expenses: 813652.00
LAB.V balance_sheet (annual, 2025-09-30) — Total Liabilities Net Minority Interest: 281284.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 281284.00
LAB.V balance_sheet (annual, 2025-09-30) — Total Non Current Assets: 7152543.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 7152543.00
LAB.V balance_sheet (annual, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 0.00
LAB.V balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 0.00
LAB.V income_statement (annual, 2025-09-30) — Total Unusual Items: -6618033.00
LAB.V income_statement (quarterly, 2025-09-30) — Total Unusual Items: -44122.00
LAB.V income_statement (annual, 2025-09-30) — Total Unusual Items Excluding Goodwill: -6618033.00
LAB.V income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: -44122.00
LAB.V cash_flow (annual, 2025-09-30) — Unrealized Gain Loss On Investment Securities: -1684210.00